Biotechnology

Nanoform launches "STARMAP® Online" placing AI-power at the fingertips of medicine developers

HELSINKI, May 4, 2022 /PRNewswire/ -- Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has launched its sparse-data AI solution (STARMAP® Online) as a secure online portal for direct use by its current and future partners. Since its inception i...

2022-05-04 14:35 1923

Prenetics Reports Record First Quarter 2022 Preliminary Financial Results. Nasdaq Listing in Partnership with Artisan Acquisition Corp. Expected on May 18, 2022[1]

Continues to Deliver Strong Results and Significant Growth   First Quarter 2022 Highlights * Revenue for the first quarter of 2022 was US$92.0 million, a record high, compared to US$57.5 million in the first quarter of 2021 * (Loss)/profit from operations under IFRS was US$(0.6) million in ...

2022-05-04 09:05 2773

Why Scaleups like Sophie's Bionutrients are Flocking to Food (not Silicon) Valley

Biotech Scaleup Sophie's Bionutrients Celebrates Earth Day and Six Months in Europe's "Food Valley" WAGENINGEN, Netherlands, May 3, 2022 /PRNewswire/ -- Six months ago, micro-algae protein pioneer Sophie's Bionutrients decided to move itsSingapore headquarters to the global alt-protein hotspot ...

2022-05-03 23:33 6047

Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler

* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs * Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim inGermany, where he is both Senior Vice Preside...

2022-05-02 07:36 3365

Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

SINGAPORE, May 1, 2022 /PRNewswire/ -- Leaders in reproductive medicine from more than 100 countries were today urged to help prevent women suffering from the debilitating effects of endometriosis from embarking on "diagnostic misadventures." Speaking at the 2022 Congress of the Asia Pacific I...

2022-05-01 16:00 9820

Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Linking male infertility diagnosis with the window to future health trajectories

SINGAPORE, May 1, 2022 /PRNewswire/ -- Male infertility factors are emerging as likely biomarkers for later life health events including hospital treatments and possible premature death from conditions such as cancer, cardiovascular and metabolic diseases. Lifestyle and social factors, includi...

2022-05-01 13:30 4985

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...

2022-05-01 06:00 3792

Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% ...

2022-04-30 04:16 9426

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onc...

2022-04-29 22:30 2989

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets...

2022-04-29 20:00 2770

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

FREDERICK, Md., April 29, 2022 /PRNewswire/ -- Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio's protease inhibitors and ...

2022-04-29 01:00 2324

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China, April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies ...

2022-04-28 22:30 2000

ReviR Therapeutics Announces Dr. David Dornan as Independent Board Director

SOUTH SAN FRANCISCO, Calif., April 28, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the appointment of Dr.David Dornan as an independent director. "We are thrilled to welcome David to our board of direc...

2022-04-28 22:00 1638

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and Aimmax Therapeutics, Inc. ( United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel ...

2022-04-28 20:00 1438

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...

2022-04-28 17:06 2127

The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine

The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, withinDenmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enable...

2022-04-28 14:00 2892

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...

2022-04-27 19:40 1630

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

* This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a more reliable way to assess the range of injury recorded as "hepatocyte ballooning" as a clinical trial endpoint by expert hepatopatholo...

2022-04-27 17:34 2270

Samsung Biologics Reports First Quarter 2022 Financial Results

* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...

2022-04-27 14:42 1783

Zymo Research Makes Strategic Investment in Star Array to Develop an Automated Nucleic Acid Extraction/Superfast PCR Platform for the POCT Market

IRVINE, Calif., April 27, 2022 /PRNewswire/ -- Zymo Research and Star Array today announced Zymo Research's strategic investment to acquire an interest in Star Array, a privately owned, biomedical technology company based inSingapore. The investment allows Zymo Research and Star Array to combine ...

2022-04-27 11:00 2657
1 ... 177178179180181182183 ... 307